Wegene Bio: Received Notice of Acceptance of Drug Registration Clinical Trial.

Weiguang Bio announced that the company has recently received the "Acceptance Notice" of the application for clinical trial registration of domestically produced subcutaneous injection human immunoglobulin issued by the National Medical Products Administration. The drug name is subcutaneous injection human immunoglobulin, with a specification of 2g/vial, and the registration classification is biological products for therapeutic use class 3.2. The drug is indicated for primary immunodeficiency diseases such as X-linked agammaglobulinemia, common variable immunodeficiency, immunoglobulin G subclass deficiency, etc.